Nexien BioPharma, Inc (OTC: NXEN) Developing a cannabinoid-based drug pipeline.

November 14, 2018 admin CEO Interview, Healthcare Comments Off on Nexien BioPharma, Inc (OTC: NXEN) Developing a cannabinoid-based drug pipeline.
Alex Wasyl, CEO Nexien BioPharma

 

Discover Tomorrow’s Winning Stocks!
Get our latest stock reports before everyone else! Actionable news, and breakout stocks w multi-bagger upside potential — delivered directly to your inbox.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.

 

 

Alex Wasyl, CEO Nexien BioPharma

 

 

 

 

 

 

Nexien BioPharma, Inc (OTC: NXEN) CEO Interview with Alex Wasyl discussing the company’s cannabinoid-based drug development pipeline. Drug development targets include, epliepsy, myotonia and other markets.




Related Articles

Newsmakers

Medicine Man Technologies (OTC: MDCL) Unveils its Largest Deal Yet with Entry into a Term Sheet to Acquire a Group of Dispensaries Operating under the Starbuds Brand

September 3, 2019 admin Newsmakers Comments Off on Medicine Man Technologies (OTC: MDCL) Unveils its Largest Deal Yet with Entry into a Term Sheet to Acquire a Group of Dispensaries Operating under the Starbuds Brand

– The Company’s addition of a group of five dispensaries will increase the retail footprint and regional coverage of the Company in Colorado- As part of the agreement, one of the original industry pioneers, Brian […]

CEO Interview

Hill Street Beverage Company (CSE: BEER) (OTC: HSEEF) Leveraging alcohol-free wine and beer into cannabis market

May 17, 2019 admin CEO Interview, Consumer Comments Off on Hill Street Beverage Company (CSE: BEER) (OTC: HSEEF) Leveraging alcohol-free wine and beer into cannabis market

  Discover Tomorrow’s Winning Stocks! Thank you for subscribing. Something went wrong. Get our latest stock reports before everyone else! Actionable news, and breakout stocks w multi-bagger upside potential — delivered directly to your inbox. […]

CEO Interview

BrainStorm Cell Therapeutics (NASDAQ: BCLI) Stem cell therapy for ALS in Phase III FDA trials

December 23, 2018 admin CEO Interview, Healthcare Comments Off on BrainStorm Cell Therapeutics (NASDAQ: BCLI) Stem cell therapy for ALS in Phase III FDA trials

  Discover Tomorrow’s Winning Stocks! Thank you for subscribing. Something went wrong. Get our latest stock reports before everyone else! Actionable news, and breakout stocks w multi-bagger upside potential — delivered directly to your inbox. […]